QPPV.COM KNOWLEDGE ASSESSMENT

Ensartinib (Gevalka): ALK Inhibition, Clinical Development and Pharmacovigilance in ALK-Positive NSCLC

Test your understanding of the concepts covered by Ensartinib (Gevalka): ALK Inhibition, Clinical Development and Pharmacovigilance in ALK-Positive NSCLC.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient develops bradycardia while taking ensartinib and a medicine that also lowers heart rate. What is the most appropriate pharmacovigilance interpretation?

The concomitant medicine is irrelevant because ensartinib is targeted therapy. The concomitant medicine is part of the causal context and should be evaluated alongside heart rate, symptoms and ECG findings. The event should automatically be attributed exclusively to ensartinib. The event should be excluded from assessment unless it is grade 3 or higher.

Question 2 of 10 A report describes tumour progression during ensartinib treatment. Which interpretation best reflects the article's approach to lack of effect?

Progression alone proves that the product caused an adverse drug reaction. Progression should be reviewed in context, including molecular classification, resistance, adherence, exposure and disease site. Progression should be excluded from product-level review because it is expected in oncology. Progression establishes that the patient's original ALK test was incorrect.

Question 3 of 10 What did the crizotinib-resistant phase II programme contribute to the ensartinib evidence base?

It established that ensartinib has no CNS activity. It provided evidence of systemic and intracranial activity after crizotinib and reinforced the rash and liver-enzyme safety pattern. It demonstrated superiority to all later-generation ALK inhibitors. It replaced the need for the randomised eXALT3 trial.

Question 4 of 10 Which statement best captures the article's overall approach to product-specific surveillance for ensartinib?

Count adverse-event terms without collecting clinical details to avoid interpretation bias. Combine routine case processing with targeted clinical follow-up and aggregate review of coherent safety domains. Focus exclusively on rash because it is the most frequent adverse reaction. Stop surveillance once a regulator has issued an approval or positive opinion.

Question 5 of 10 Why should a safety team seek more detail than the term "rash" when reviewing a dermatologic report?

All rash reports necessarily indicate a severe cutaneous reaction. Morphology, severity, mucosal or systemic involvement and outcome distinguish common manageable rash from more serious phenotypes. Rash is not part of the ensartinib safety profile. The only clinically relevant detail is whether the patient had brain metastases.

Question 6 of 10 After a new local product-information document becomes effective, which operational response is most consistent with the article's governance principles?

Update only the public product webpage. Use controlled change management to propagate the change to relevant case-processing, signal, aggregate and training materials. Wait until a new clinical trial is completed before changing internal procedures. Continue using the previous reference information for all cases to preserve consistency.

Question 7 of 10 What conclusion is most appropriately supported by the eXALT3 trial's comparison of ensartinib with crizotinib?

Ensartinib is superior to every later-generation ALK inhibitor. Ensartinib showed improved progression-free survival versus crizotinib in the trial population. Ensartinib prevents acquired resistance in ALK-positive NSCLC. Ensartinib is more effective than all available treatments in every treatment line.

Question 8 of 10 According to the US prescribing information discussed in the article, what is the stated management action for ensartinib-associated ILD/pneumonitis?

Continue treatment and monitor symptoms without interruption. Reduce the dose and routinely rechallenge after resolution. Permanently discontinue ensartinib. Discontinue only if the event occurs after the first year.

Question 9 of 10 Which information is most useful when evaluating a possible ensartinib-related hepatic injury?

Serial ALT, AST, alkaline phosphatase and bilirubin values, timing, symptoms and competing causes. The patient's tumour stage alone. A single statement that liver enzymes were elevated, without dates or values. The presence or absence of CNS metastases only.

Question 10 of 10 A safety database combines all ensartinib cases from multiple regions but does not retain the local reference information used for expectedness. What is the main concern?

The database may fail to support jurisdiction-specific expectedness and reporting assessments. The database cannot be used for any global signal detection. The database will necessarily overestimate the biological frequency of every adverse reaction. The database makes treatment-line information unnecessary.

QPPV.com

Ensartinib (Gevalka): ALK Inhibition, Clinical Development and Pharmacovigilance in ALK-Positive NSCLC

Cookie Settings